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Four unrelated individuals have been identified with an identical antithrombin variant, associated in one of them with episodes of recurrent venous 
thromboses. In each case, the plasma antithrombin concentration was normal and the only functional abnormality was a minor but consistent 
decrease in the heparin-induced thrombin inhibition suggesting a mutation at or near the reactive centre of the molecule. Amplification and direct 
sequencing of exon 6 showed a G-*T mutation at nucleotide 1246, which corresponds to a substitution of a serine for an alanine at residue 384. 
This is one of a series of conserved alanincs that form the stalk to the reactive ccntre loop. The observed changes in this variant are compatible 
with recent structural studies that infer that mobility of this stalk with partial re-entry into the A-sheet of the molecule is necessary for optimal 
inhibitory activity. 
Antithrombin; PCR; Active site variant 
I. INTRODUCTION 2. A4ATERIALS AND METHODS 
Human antithrombin III (here referred to as an- 
tithrombin) is a 58 kDa plasma glycoprotein belonging 
to the Serpin superfamily. It is the major inhibitor of a 
number of serine proteases involved in coagulation, in- 
cluding factor IIa (thrombin) and factor Xa [l]. Under 
normal physiological conditions its inhibitory activity is 
relatively slow, but in the presence of heparin this ac- 
tivity is increased by IOOO-fold [ 11. The importance of 
amtithrombin in the regulation of normal haemostasis 
is emphasised by the recurrent thromboses that in- 
dividuals with either a deficient or abnormal antithrom- 
bin are prone to develop [2]. 
We have used the polymerase chain reaction (PCR) 
[3] to amplify exon 6 [4] of the antithrombin gene in 
four patients with an antithrombin variant which ex- 
hibited heparin binding but defective inhibitory activi- 
ty. The identified mutation provides srlpport for the 
proposal that inhibitory activity of the serpins is depen- 
dent on a folding of the N-terminal region of the reac- 
tive centre loop. 
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2. I . Materials 
All reagents unless otherwist stated were obtained from the Sigma 
Chemical Co., Poole, Dorset, UK. Deoxynucleotides and T4 
polynucleotide kinase were obtained from Pharmacia-LKB 
Biotechnology, Milton Keynes, UK; Thermus Aquaticus (Taq) 
polymerase from Perkin-Elmer Cetus, Beaconsfield, UK; low melting 
point agarose from BioRad Labs Ltd., Watford, 55:; i’!trz:~~Jre urea, 
agarose and restriction enzymes from Gibco-BRL. Paisley, Scotland. 
DNA sequencing used Sequenase ~2.0 obtained from United States 
Biochemical Corporation (Cambridge Bioscience), Cambridge, UK. 
Chromogenic substrate Chromozym TH was obtained from Boehr- 
inger Mannheim, Lewes. E. Sussex and S2222 from Kabi Vitrum. Ux- 
bridge, Middx. 
2.2. Patiertts 
Patient 1 was a 68-ye&r-old male who was presented at the age of 
35 years with a deep vein thrombosis following an acute episode of 
gout and subsequently experienced two further spontaneoils ihrom- 
boses. There was no family history of thromboembolic disease. 
Patients 2, 3 and 4, were unrelated to the first patient. In each case 
there was no history of thrombocmbolic disease and the abnormality 
was detected as part of a screening programme of normal blood 
donors to establish the incidence of antithrombin deficiency. 
2.3. Plasma antithrombin ussays 
Antithrombin antigen was measured by competitive ELlSA [.5]. 
Antithrombin anti-lla activity was measured in the absence (an- 
tithrombin progressive activity) or in the presence of heparin (heparin 
cofactor activity) according to Abildgaard [6] using the chromogenic 
substrate Chromozym TH. Anti-Xa activity was performed according 
to Odegard [7] in the presence of heparin (anti-Xa heparin cofactor) 
using the substrate S2222. Crossed immunoelectrophoresis was per- 
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formed according to Sas [X] with and without the addition of heparin 
(25 U/ml) in the first dimension. 
2.4. Atnplificalion and sequencing of exon 6 of the antilhrombin 
gene 
DNA was isolated from peripheral blood leucocytes as previously 
described [9]. 
Synthetic oligonucleotides S’AATGAACACAAGTGTTTGGT- 
TTTTAT and 5’-AAGCATTGAGGAATTGCTGTGTCTGT were 
designed to selectively amplify a 249-base pair (bp) region of the AT 
gene encompassing the entire coding region of exon 6 together with 
some 5’-intronic and 3 ‘-untranslated sequence. The PCR product 
was gel-purified and directly sequenced using a “P-labelled ‘nested’ 
sequencing primer [lo]. 
3. RESULTS 
Plasma antithrombin assays (Table I) demonstrated 
normal antigenic levels of antithrombin, normal pro- 
gressive inhibitory activity and normal heparin induced 
anti-Xa activity. However, anti-lla activity in the 
presence of heparin was reduced to 76% in two cases 
and to 30% and 59% in the remaining two cases. Cross- 
ed immunoelectrophoresis showed an identical mobility 
of the normal and abnormal components both in the 
presence and absence of heparin. 
DNA was isolated from peripheral blood leucocytes. 
In the four patients studied, amplification of exon 6 of 
the AT gene generated a single fragment of 249 bp. Se- 
quencing of the PCR product demonstrated two bands 
at nucleotide position 1246 representing the normal 
guanine (G) and the mutant thymidine (T) bases. The 
sequences for codon 384 derived from the anti-sense 
strand are, therefore, GCA coding for alanine and TCA 
coding for serine. 
This mutation is associated with the loss of a Pvctll 
site, which allows for the rapid screening of family 
members. Testing of related family members has iden- 
tified the mutation in a further two asymptomatic 
siblings. 
4. DISCUSSION 
We report here an antithrombin variant, Cambridge 
II, found in four unrelated heterozygotes, in only one 
Ala 384 (Pl 0) Pro AT111 Cambridge 1 
Ser AT111 Cambridge 2 
la 382 (Pl?) ‘Thr AT111 Hamilton 
Val Ovalbumin 
Fig. I. Projection of antithrombin on the reactive centre of 
ovalbumin [13], avertical view of that shown in Fig. 28, indicating the 
position of the N-terminal stalk substitutionsat alanine 384 (PIO), ten 
residues from the reactive center (PI) and at alanine 382 (PIZ). 
of whom there was a history of recurrent venous throm- 
boses. The variant 384 Ala to Ser has properties in com- 
mon with similar variants having mutations at or near 
the active site (Fig. l), i.e. normal heparin binding but 
a loss of thrombin inhibitory activity. However, a uni- 
que feature of the Cambridge II variant (Table I) is that 
it retains anti-Xa activity whereas others, including the 
same site 384 Ala to Pro [IO,1 I] lose both IIa and Xa in- 
hibitory activity. 
Although these results may seem puzzling, they fit 
well both with current proposals as to the structural 
basis of inhibition in the serpin family (reviewed by 
Huber and Carrel1 [12]) and with the structural model 
for a mobile reactive centre recently presented by Stein 
et al. [13]. There is now good evidence that the reactive 
centre of antithrombin, Arg-Ser 393-394, lies on an ex- 
ternal peptide loop hinged on Glu-377 and extending to 
Arg-393. It is believed that a critical contribution of this 
loop is to hold the reactive centre in an available and 
strained conformation. 
A proposed basis for the strain is the inability of the 
loop, in the intact antithrombin, to move fully back in- 
to the adjacent A sheet, where it would form a more 
stable conformation, as occurs spontaneously on 
cleavage of the loop [14]. The resultant conformation 
of the loop on incomplete m-entry into the sheet is likely 
to be close to that of the canonical form found in other 
Table I 
Alanine 382 and 384 variants 
Inhibitory Activity (070) 
+ Heparin - Heparin Antigenic Reference 
Variant Mutation Ila 
(xsL15, 
Ila cone (070) 
(85-133) (76-97) (70-126) 
Patient 1 Ala-+Ser 384 76 99 100 103 
Patient 2 Ala-+Ser 384 76 101 120 106 
Patient 3 Ala-+Ser 384 30 80 113 
Patient 4 Ala-+&r 384 59 147 104 I08 
Cambridge I” A!a+Pro 384 54 43 63 95 
I-lamilton” 
Perry et al, 1988 [9] 
Ala+Tbr 382 55 59 50 98 Devraj-Kizuk et nl., 1988 [15] 
“ATIII Charleville - identical variant [II]. 
“Data refers to an AT Hamilton variant identified locally. 
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(a) Ovalbumin 
(b) ‘Antithrombin’ mo 
PI Au 393 
Ah 382 
PM Ser 380 
klix D 
Fig. 2. Diagrammatic models of the A-sheet and reactive centre loop 
of (a) ovalbumin [13] and(b) of antithrornbin modelled to show how 
partial re-entry of strand 4 into the A sheet would give a loop structure 
approximating to the optimal inhibitory conformation. Re-entry of 
the loop to give strand 4 (s4a) is incomplete and can be modelled 
beyond this point for perhaps one or two residues emphasising the 
need for flexibility at PI0 and PI2 (382 and 384 in antithrombin). 
families of serine proteinase inhibitors [15] that mat- 
ches the active site of the protease (Fig. 2). This need to 
maintain mobility provides an explanation for the con- 
servation throughout the inhibitor members of the 
family, of a trio of amino acids with low-bulk side 
chains, usualIy -Ala-Ala-AIa-, at a position, near the 
proposed bend of the loop, 382-384 in antithrombin 
[12,13]. 
Alanine 382 is strongly conserved throughout the in- 
hibitor serpins and its replacement by threonine in an- 
tithrombin Hamilton [16] results in a loss of inhibitory 
activity. Alanine 384 is less strictly conserved and hence 
likely to, be less critical for function. This is in keeping 
with the observation that a major change such as the 
replacement of alanine 384 by proline [IO] causes an ap- 
parently complete loss of activity whereas the less 
drastic substitution of the alanine by a sizrine causes on- 
ly a selective loss of inhibition. 
Although the presence of a row of alanines suggests 
a requirement for flexibility, there will also be steric and 
polarity requirements in order for these residues to fit in 
place as they fold back into the A-sheet. Evidence for 
the requirements of fit comes from binary complexing 
experiments in which a synthesised peptide with the se- 
quence of the active centre loop of antithrombin 
380-392 (P2-P14) can be shown to anneal in the A- 
sheet in the intact inhibitors [17]. Replacement of the 
382 (P12) alanine by threonine as in AT Hamilton gives 
a much slower annealing indicating a decrease in the fit 
of the threonine in the A-sheet (D. Evans et al., un- 
published). The same experiments have not been tried 
with the new AT Cambridge I1 mutant but it is difficult 
to see from the model (Fig. 2b) how reincorporation of 
residue 384 could occur in the intact protein even to give 
the fully stretched canonical form of the reactive centre. 
It is likely then that the AT Cambridge II mutation will 
primarily affect the mobility of the loop rather than its 
ability to fit sterically into the A-sheet. 
The observed findings with these mutants of an- 
tithrombin fit with the changes that follow loosening of 
the loop by the insertion of an extra residue as in the 
natural variant antiplasmin Enschede [18] which loses 
its inhibitory activity, and with site-directed mutants of 
antitrypsin in which the addition of a residue alters the 
specificity, as well as activity of inhibition [19]. Thus, 
the overall results are compatible with a role for 
alanines 382-384 in the maintenance of the flexibility of 
the reactive centre as well as its ability to fit back into 
the A-sheet. 
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